Table of Contents Author Guidelines Submit a Manuscript
Genetics Research International
Volume 2011, Article ID 798089, 4 pages
Review Article

Genetic Markers Used for Risk Stratification in Multiple Myeloma

1Laboratory of Molecular Biology, Bone Marrow Transplantation Center, National Cancer Institute, Rio de Janeiro, RJ 20230-130, Brazil
2Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259-5494, USA

Received 31 May 2011; Accepted 14 July 2011

Academic Editor: Norma C. Gutierrez

Copyright © 2011 Priscilla Segges and Esteban Braggio. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


While no specific genetic markers are required in the diagnosis of multiple myeloma (MM), multiple genetic abnormalities and gene signatures are used in disease prognostication and risk stratification. This is particularly important for the adequate identification of the high-risk MM group, which does not benefit from any of the current therapies, and novel approaches need to be proposed. Fluorescence in situ hybridization (FISH) has been employed for establishing risk-based stratification and still remains the most used genetic technique in the clinical routine. The incorporation of gene expression profiling (GEP) in the study of MM has shown to be a very powerful test in the patient stratification, but its incorporation in clinical routine depends on some technical and logistic resolutions. Thus, FISH still remains the gold standard test for detecting genomic abnormalities and outcome discrimination in MM.